EIKN (NASDAQ:EIKN) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of EIKN (NASDAQ:EIKN) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

EIKN has been the subject of several other research reports. Cantor Fitzgerald initiated coverage on EIKN in a research report on Monday, March 2nd. They set an “overweight” rating for the company. Bank of America assumed coverage on EIKN in a report on Monday, March 2nd. They issued a “buy” rating and a $34.00 target price on the stock. Zacks Research raised EIKN to a “hold” rating in a research report on Friday, February 27th. Morgan Stanley initiated coverage on EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, EIKN currently has an average rating of “Moderate Buy” and an average target price of $25.60.

EIKN Stock Up 3.7%

EIKN stock opened at $14.91 on Friday. EIKN has a 52-week low of $13.28 and a 52-week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.